Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Aug 1;11(8):349.
doi: 10.3390/vetsci11080349.

Microbiota in Mild Inflammatory Bowel Disease (IBD) Can Be Modulated by Beta-Glucans and Mannanoligosaccharides: A Randomized, Double-Blinded Study in Dogs

Andressa Rodrigues Amaral  1 , Mariana Fragoso Rentas  2 , Thais Caroline Taveira Rosa  1 , Thais Araújo Esteves Pereira  1 , Pedro Henrique Marchi  2 , Fabio Alves Teixeira  1 , Fernando de Oliveira Roberti Filho  3 , Thaila Cristina Putarov  4 , Bruno Cogliati  5 , Thiago Henrique Annibale Vendramini  1   2 , Júlio Cesar de Carvalho Balieiro  2 , Marcio Antonio Brunetto  1   2
Affiliations

Microbiota in Mild Inflammatory Bowel Disease (IBD) Can Be Modulated by Beta-Glucans and Mannanoligosaccharides: A Randomized, Double-Blinded Study in Dogs

Andressa Rodrigues Amaral et al. Vet Sci. .

Abstract

Inflammatory bowel disease (IBD) in dogs is the most common chronic gastrointestinal disease in dogs. Its etiology evolves an aberrant immunological response towards food antigens and indigenous bacteria in the gut bacteria and, consequently, dysbiosis. Prebiotics provide substrates for the growth of beneficial bacteria and promote the production of beneficial fermentation products. This study aimed to evaluate the effects of oral supplementations of beta-glucans and mannanoligosaccharides (MOSs) over 60 days in fecal microbiota and fecal concentrations of fermentation products in dogs with mild IBD. Eighteen dogs with mild IBD were divided into three experimental groups in a blinded and randomized manner: A-dogs received 0.1% of a beta-glucan-based prebiotic, B-dogs received 0.1% of a MOS + beta-glucan-based prebiotic, and C-dogs received 0.1% of a placebo. Fecal microbiota was analyzed using the latest generation 16S rRNA sequencing (Illumina®). Relative abundances of each taxon were analyzed using a generalized linear model, and fermentation products using a mixed model. A significance level of p was used. The prebiotics positively modulated the bacterial population of Firmicutes and Bacteroidetes. Treatment A improved alpha diversity and populations of beneficial bacteria. Beta-glucan supplementation for 60 days had beneficial effects on modulating intestinal microbiota in dogs with mild IBD.

Keywords: chronic enteropathy; dog; dysbiosis; nutrition; prebiotic.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest. Fabio Alves Teixeira works as a consultant for companies in the supplementation sector.

Figures

Figure 1
Figure 1
Mean values of BW (a), BCS (b), MMS (c), CCECAI (d), FS (e) at T0 and T60. A: 1.3/1.6 beta-glucan; B: MOS + 1.3/1.6 beta-glucan; C: placebo.
Figure 2
Figure 2
Fecal concentration of short and branched-chain fatty acids in the experimental groups. A: 1.3/1.6 beta-glucan; B: 1.3/1.6 beta-glucan + MOS; C: placebo.
Figure 3
Figure 3
Three-dimensional analysis of the main components with the absolute data obtained by sequencing the samples of the three experimental groups at T0 and T60. A: 1.3/1.6 beta-glucan; B: 1.3/1.6 beta-glucan + MOS; C: placebo.
Figure 4
Figure 4
Average percentages of phyla of Actinobacteria (a), Bacteroidetes (b), Firmicutes (c), Fusobacteria (d), and Proteobacteria (e) at T0 and T60 in experimental groups. A: 1.3/1.6 beta-glucan; B: 1.3/1.6 beta-glucan + MOS; C: placebo; * p < 0.05.
Figure 5
Figure 5
Average percentages of classes of Actinobacteria (a), Coriobacteria (b), Bacteroidia (c), Bacilli (d), Clostridia (e), Erysipelotrichi (f), Fusobacteria (g), and Gammaproteobacteria (h). A: 1.3/1.6 beta-glucan; B: 1.3/1.6 beta-glucan + MOS; C: placebo; * p < 0.05.
Figure 5
Figure 5
Average percentages of classes of Actinobacteria (a), Coriobacteria (b), Bacteroidia (c), Bacilli (d), Clostridia (e), Erysipelotrichi (f), Fusobacteria (g), and Gammaproteobacteria (h). A: 1.3/1.6 beta-glucan; B: 1.3/1.6 beta-glucan + MOS; C: placebo; * p < 0.05.
Figure 6
Figure 6
Average percentages of families of Actinomycetaceae (a), Coriobacteriaceae (b), Bacteroidaceae (c), Enterococcaceae (d), Streptococcaceae (e), Clostridiaceae (f), Lachnospiraceae (g), Peptostreptococcaceae (h), Ruminococcaceae (i), Erysipelotrichaceae (j), Fusobacteriaceae (k), Enterobacteriaceae (l), and Pseudomonadaceae (m). A: 1.3/1.6 beta-glucan; B: 1.3/1.6 beta-glucan + MOS; C: placebo. * p < 0.05.
Figure 6
Figure 6
Average percentages of families of Actinomycetaceae (a), Coriobacteriaceae (b), Bacteroidaceae (c), Enterococcaceae (d), Streptococcaceae (e), Clostridiaceae (f), Lachnospiraceae (g), Peptostreptococcaceae (h), Ruminococcaceae (i), Erysipelotrichaceae (j), Fusobacteriaceae (k), Enterobacteriaceae (l), and Pseudomonadaceae (m). A: 1.3/1.6 beta-glucan; B: 1.3/1.6 beta-glucan + MOS; C: placebo. * p < 0.05.
Figure 7
Figure 7
Average percentages of genera of Actinomyces (a), Collinsella (b), Bacteroides (c), Enterococcus (d), Streptococcus (e), Clostridium (f), Ruminococcus (g), Blautia (h), Dorea (i), Pseudomonas (j), and Eubacterium (k). A: 1.3/1.6 beta-glucan; B: 1.3/1.6 beta-glucan + MOS; C: placebo. * p < 0.05.
See this image and copyright information in PMC

References

    1. Minamoto Y., Otoni C.C., Steelman S.M., Büyükleblebici O., Steiner J.M., Jergens A.E., Suchodolski J.S. Alteration of the Fecal Microbiota and Serum Metabolite Profiles in Dogs with Idiopathic Inflammatory Bowel Disease. Gut Microbes. 2015;6:33–47. doi: 10.1080/19490976.2014.997612. - DOI - PMC - PubMed
    1. Cave N. Nutritional Management of Gastrointestinal Diseases. In: Fascetti A.J., Delaney S.J., editors. Applied Veterinary Clinical Nutrition. Wiley-Blackwell Publishing Ltd.; Hoboken, NJ, USA: 2013. pp. 175–219.
    1. Davenport D.J., Jergens A.E., Remmilard R. In: Inflammatory Bowel Disease. In Small Animal Clinical Nutritional. Hand M.S., Thatcher C.D., Remillard R.L., Roudebush P., Novotny B.J., editors. Mark Morris Institute; Topeka, KS, USA: 2010. pp. 1065–1076.
    1. Matsuoka K., Kanai T. The Gut Microbiota and Inflammatory Bowel Disease. Semin. Immunopathol. 2015;37:47–55. doi: 10.1007/s00281-014-0454-4. - DOI - PMC - PubMed
    1. Blake A.B., Suchodolski J.S. Importance of Gut Microbiota for the Health and Disease of Dogs and Cats. Anim. Front. 2016;6:37–42. doi: 10.2527/af.2016-0032. - DOI

LinkOut - more resources